Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

EssilorLuxottica: Appointment of Eight Directors

The Board of Directors of EssilorLuxottica has decided to submit to the General Assembly on April 28, 2026, the appointment of eight directors whose terms are expiring.


EssilorLuxottica: Appointment of Eight Directors

Proposed Appointments for Directors

Four directors are proposed for a three-year term: Romolo Bardin, José Gonzalo, Virginie Mercier-Pitre, and Swati Piramal. Another four directors are proposed for a two-year term: Mario Notari, Cristina Scocchia, Nathalie von Siemens, and Andrea Zappia.

Staggered Term Expirations

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

In accordance with the staggered terms, the three-year terms of Francesco Milleri, Paul du Saillant, Jean-Luc Biamonti, and Marie-Christine Coisne-Roquette will expire in 2027. The terms of the directors representing the employees, Margot Bard and Sébastien Brown, were renewed in 2024 for a duration of three years.



Sector Luxe Fournitures Médicales


Assurance vie

Context

Period
  • Period: 2025
Key reported figures
  • Revenue: 28 491 millions d'euros
  • Revenue growth: 11,2 %
  • EBITDA: 6 492 millions d'euros
  • EBITDA margin: 22,8 %
  • Net income: 2 443 millions d'euros
  • Free cash flow: 2 796 millions d'euros
  • Net debt: 10 853 millions d'euros
  • Dividend per share: 4,00 euros
Guidance from the release
  • C’est une année historique pour EssilorLuxottica : pour la première fois depuis l’origine du Groupe, notre chiffre d’affaires a enregistré une croissance à deux chiffres à taux de change constant, après un quatrième trimestre affichant une croissance record de 18,4 %.
  • Résultats annuels 2025 marquent une croissance du chiffre d’affaires de 11,2% et une marge opérationnelle ajustée de 15,7%; le cash-flow libre atteint 2,8 milliards d'euros; dividende proposé de 4,00 euros; acquisitions et initiatives med-tech renforcent le positionnement.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit